Literature DB >> 1455983

Treatment of myotonia with antiarrhythmic drugs.

H Kwieciński1, B Ryniewicz, A Ostrzycki.   

Abstract

The effects of disopyramide, phenytoin, mexiletine, and tocainide were compared in 30 patients with myotonic disorders. The severity of myotonia was assessed by clinical and electromyographic criteria at the end of each treatment phase lasting four weeks. Mexiletine (MXT) and tocainide (TCD) were found to be the most potent antimyotonic agents. The antimyotonic efficacy of MXT and TCD is explained by their fast-blocking effect on voltage-dependent sodium channels in the muscle membrane. The benefits of myotonia control with pharmacological agents must be weight against the risk of therapy in the individual patient. Because of the risks of hematologic problems, TCD is not recommended by us for the treatment of myotonia.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1455983     DOI： 10.1111/j.1600-0404.1992.tb05103.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN： 0001-6314            Impact factor:   3.209


  25 in total

1.  Channelopathies.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-01       Impact factor: 3.598

2.  Open-label trial of ranolazine for the treatment of paramyotonia congenita.

Authors:  Samantha Lorusso; David Kline; Amy Bartlett; Miriam Freimer; Julie Agriesti; Ahmed A Hawash; Mark M Rich; John T Kissel; W David Arnold
Journal:  Muscle Nerve       Date:  2018-12-21       Impact factor: 3.217

Review 3.  Inherited disorders of voltage-gated sodium channels.

Authors:  Alfred L George
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

4.  Case 12: my doctor says that I have ALS!

Authors:  Robin K Wilson; Vinay Chaudhry
Journal:  MedGenMed       Date:  2006-03-22

5.  Open-label trial of ranolazine for the treatment of myotonia congenita.

Authors:  W David Arnold; David Kline; Alan Sanderson; Ahmed A Hawash; Amy Bartlett; Kevin R Novak; Mark M Rich; John T Kissel
Journal:  Neurology       Date:  2017-07-14       Impact factor: 9.910

Review 6.  Diagnostics and therapy of muscle channelopathies--Guidelines of the Ulm Muscle Centre.

Authors:  F Lehmann-Horn; K Jurkat-Rott; R Rüdel
Journal:  Acta Myol       Date:  2008-12

7.  Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1.

Authors:  E L Logigian; W B Martens; R T Moxley; M P McDermott; N Dilek; A W Wiegner; A T Pearson; C A Barbieri; C L Annis; C A Thornton; R T Moxley
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

Review 8.  Guidelines on clinical presentation and management of nondystrophic myotonias.

Authors:  Bas C Stunnenberg; Samantha LoRusso; W David Arnold; Richard J Barohn; Stephen C Cannon; Bertrand Fontaine; Robert C Griggs; Michael G Hanna; Emma Matthews; Giovanni Meola; Valeria A Sansone; Jaya R Trivedi; Baziel G M van Engelen; Savine Vicart; Jeffrey M Statland
Journal:  Muscle Nerve       Date:  2020-05-27       Impact factor: 3.217

9.  Inhibition of skeletal muscle sodium currents by mexiletine analogues: specific hydrophobic interactions rather than lipophilia per se account for drug therapeutic profile.

Authors:  Annamaria De Luca; Sophie Talon; Michela De Bellis; Jean-François Desaphy; Carlo Franchini; Giovanni Lentini; Alessia Catalano; Filomena Corbo; Vincenzo Tortorella; Diana Conte-Camerino
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-25       Impact factor: 3.000

10.  Nondystrophic myotonia: challenges and future directions.

Authors:  Jaya R Trivedi; Stephen C Cannon; Robert C Griggs
Journal:  Exp Neurol       Date:  2013-12-18       Impact factor: 5.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.